dostarlimab (Jemperli®)
Application Details
HSE100106
26020
dostarlimab
Jemperli®
GlaxoSmithKline Limited
07/05/2026
15/01/2025
Application Status
Full Health Technology Assessment Commissioned by HSE
22/05/2026
Rapid Review Completed
21/05/2026
Pricing and Reimbursement Application Complete
07/05/2026
Rapid Review Commissioned
06/05/2026